Puretech Health (PRTC) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Zentalis Pharmaceuticals and PureTech Health Get Fast Track Designation From FDA for Their Cancer Treatments
Seeking AlphaJan 9 07:52 ET
Express News | The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia
BenzingaJan 9 07:08 ET
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
BusinesswireJan 8 07:00 ET
PureTech Appoints UBS as UK Corporate Broker
BusinesswireJan 6 02:00 ET
Leerink Partners Maintains Puretech Health(PRTC.US) With Buy Rating, Raises Target Price to $46
Moomoo NewsDec 16, 2024 20:32 ET · Ratings
12 Health Care Stocks Moving In Monday's Pre-Market Session
BenzingaDec 16, 2024 16:05 ET

Comments

Jaguar8

Jan 12 16:02

🟢 Watchlist JANUARY 13, 2025, Monday. NFA. Those with 🟢 are my top picks

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you don’t a...

73

30

9

Jaguar8

Jan 9 15:27

🔵 Watchlist JANUARY 10,2025, Friday. NFA. Quite long because of Wednesday’s red day and Thursday good news… in progress

NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...

109

35

16

Jaguar8

Jan 9 14:10

NEWS

$Puretech Health (PRTC.US)$
The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia
Benzinga· 04:081min
Puretech Health(PRTC.US)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatmentLYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers

PRTC Puretech Health

Trade Overview

Capital Trend

News

Comments